Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.

Molecular carcinogenesis - 1 Sept 2024

Liang Xiao, Xu Jiali, Jiang Yuqin, Yan Yuqian, Wu Hongshuai, Dai Jiali, Cui Yanan, Zhang Chen, Chen Wei, Zhang Zhihong, Guo Renhua

Abstract excerpt

This study aimed to explore the clinical significance of genomics features including tumor mutation burden (TMB) and copy number alteration (CNA) for advanced EGFR mutant lung cancer. We retrospectively identified 1378 patients with advanced EGFR mutant lung cancer and next-generation sequencing tests from three cohorts. Multiple co-occurring genomics alternations occurred in a large proportion (97%) of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genomics

Share to Lung Neoplasms

Share to Nomograms

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38860603
DOI: 10.1002/mc.23750

Genes

EGFR
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.PMID 38860603Read ↗

Genomic Insights into Innate Resistance in Early-Stage EGFR-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data.Semantic proximity Read ↗

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable MutationsSemantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.Semantic proximity Read ↗

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.Semantic proximity Read ↗

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung CancerSemantic proximity Read ↗

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Semantic proximity Read ↗

The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Molecular Heterogeneity Analysis and Prognostic Stratification of Driver-Gene mutated NSCLC Based on Concurrent Alteration ProfilesSemantic proximity Read ↗

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.Semantic proximity Read ↗

Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.Semantic proximity Read ↗

Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.